DK0980251T3 - Vævsfaktor til påvirkning af blodkardannelse - Google Patents

Vævsfaktor til påvirkning af blodkardannelse

Info

Publication number
DK0980251T3
DK0980251T3 DK98933500T DK98933500T DK0980251T3 DK 0980251 T3 DK0980251 T3 DK 0980251T3 DK 98933500 T DK98933500 T DK 98933500T DK 98933500 T DK98933500 T DK 98933500T DK 0980251 T3 DK0980251 T3 DK 0980251T3
Authority
DK
Denmark
Prior art keywords
tissue factor
blood vessel
vessel formation
influence blood
influence
Prior art date
Application number
DK98933500T
Other languages
Danish (da)
English (en)
Inventor
Peter Nawroth
Katsumi Nakagawa
Youming Zhang
Original Assignee
Merckle Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merckle Gmbh filed Critical Merckle Gmbh
Application granted granted Critical
Publication of DK0980251T3 publication Critical patent/DK0980251T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Instructional Devices (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
DK98933500T 1997-05-09 1998-05-08 Vævsfaktor til påvirkning af blodkardannelse DK0980251T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19719652A DE19719652A1 (de) 1997-05-09 1997-05-09 Tissue-Faktor zur Förderung von Wundheilung
DEPCT/DE98/01278 1998-05-07
PCT/DE1998/001306 WO1998051321A1 (de) 1997-05-09 1998-05-08 Tissue-faktor zur beeinflussung von gefässbildung

Publications (1)

Publication Number Publication Date
DK0980251T3 true DK0980251T3 (da) 2002-11-18

Family

ID=7829124

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98933500T DK0980251T3 (da) 1997-05-09 1998-05-08 Vævsfaktor til påvirkning af blodkardannelse

Country Status (16)

Country Link
EP (1) EP0980251B1 (is)
JP (1) JP2001527555A (is)
AT (1) ATE222501T1 (is)
AU (1) AU746782B2 (is)
CA (1) CA2288117A1 (is)
CZ (1) CZ293005B6 (is)
DE (2) DE19719652A1 (is)
DK (1) DK0980251T3 (is)
ES (1) ES2184299T3 (is)
HU (1) HUP0003831A3 (is)
IS (1) IS5231A (is)
NO (1) NO995459D0 (is)
PL (1) PL336662A1 (is)
PT (1) PT980251E (is)
SI (1) SI0980251T1 (is)
WO (1) WO1998051321A1 (is)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7749498B2 (en) 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
DE19719652A1 (de) * 1997-05-09 1998-12-03 Merckle Gmbh Tissue-Faktor zur Förderung von Wundheilung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770209A (en) * 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
AU5093593A (en) * 1992-08-28 1994-03-29 Scripps Research Institute, The Inhibition of tumor metastasis via neutralization of tissue factor function
FR2696095B1 (fr) * 1992-09-30 1994-11-25 Inoteb Colle biologique à base de protéines coagulables par la thrombine, enrichie en facteurs plaquettaires, sa préparation et son application.
JPH10502534A (ja) * 1994-07-12 1998-03-10 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド 結合組織増殖因子−２
US5981471A (en) * 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
DE19719652A1 (de) * 1997-05-09 1998-12-03 Merckle Gmbh Tissue-Faktor zur Förderung von Wundheilung

Also Published As

Publication number Publication date
CZ391299A3 (cs) 2000-04-12
ATE222501T1 (de) 2002-09-15
DE19719652A1 (de) 1998-12-03
AU746782B2 (en) 2002-05-02
ES2184299T3 (es) 2003-04-01
HUP0003831A3 (en) 2003-08-28
EP0980251B1 (de) 2002-08-21
CZ293005B6 (cs) 2004-01-14
PT980251E (pt) 2003-01-31
PL336662A1 (en) 2000-07-03
EP0980251A1 (de) 2000-02-23
SI0980251T1 (en) 2003-02-28
HUP0003831A2 (hu) 2001-02-28
JP2001527555A (ja) 2001-12-25
WO1998051321A9 (de) 1999-04-01
DE59805246D1 (de) 2002-09-26
WO1998051321A1 (de) 1998-11-19
IS5231A (is) 1999-10-26
NO995459L (no) 1999-11-08
NO995459D0 (no) 1999-11-08
AU8331598A (en) 1998-12-08
CA2288117A1 (en) 1998-11-19

Similar Documents

Publication Publication Date Title
NO944997L (no) Trombin-blodfraksjon for anvendelse ved en medisinsk fremgangsmåte
DE60023043T2 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
DE69827192D1 (de) Stent und Stent-Transplantat zur Behandlung von verzweigten Blutgefässen
DK2412368T3 (da) Sammensætning til behandling af ar
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
TR199901174T2 (xx) Yeni heterosiklilmetil-ikameli pirazol t�revleri.
TR199801390T2 (xx) Tromboz tedavisinde kullan�lacak p�ht�la�may� �nleyici maddeler
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
DE69617963T2 (de) Behandlung von titandioxidaufachlämmungen mittels scherkräften
DK0706348T3 (da) Kirurgisk instrument især til dental kirurgi.
DK1178726T3 (da) Vandig opløsning til konservering af væv og organer
DE69829217D1 (de) Vorrichtung zur therapeutischen behandlung von blutgefässen
DK0980251T3 (da) Vævsfaktor til påvirkning af blodkardannelse
DK1331940T3 (da) Anvendelse af det lange pentraxin PTX3 til behandling af sygdomme forårsaget af ændret aktivering af vækstfaktoren FGF-2
DK301190D0 (da) Bioforenelige, stof-specifikke reagenser til behandling af fysiologiske vaesker
DE3772051D1 (de) Prothese zur expansion des hautgewebes.
DE3785555D1 (de) Verwendung von guaifenesin zur behandlung urologischer beschwerden.
ATE324905T1 (de) Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall
DE69519219T2 (de) Verwendung von (2S,4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazoline]-2-carboxamid zur Behandlung von Keratopathie
DE69832075D1 (de) Verwendung von eprosartan zur behandlung von isoliertem systolischem bluthochdrucks
FR2698534B1 (fr) Fixateur externe modulaire pour ostéosynthèse des petits os, notamment de la main.
NO984965L (no) Komponent B som cicatrisant
DE69819503D1 (de) Verwendung von 7-apha-methyl-17-alpha-ethynyl-estrane derivaten zur behandlung von atherosclerose
ATE226443T1 (de) Verwendung von orosomucoid zur herstellung einer pharmazeutischen präparation zur behandlung von pankreatitis